Annexon Inc. (ANNX)
NASDAQ: ANNXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ANNX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $591.37M
- EPS (TTM)
- -$1.01
- Dividend yield
- None
- 52-week range
- 3.07 – 7.18
- Day range
- 3.07 – 3.37
- Volume / Avg
- 4.45M / 3.36M
- Beta
- —
- Shares outstanding
- 190.76M
52-week range
ANNX stock today
Annexon (ANNX) closed at $3.10 on Nov 20, down 9.09% (-$0.31), versus the S&P 500's 3.70% decline. Shares are 56.8% below their 52-week high of $7.18, set on Jan 23, 2026 and 1.0% above the 52-week low of $3.07, near the bottom of the past year's range. ANNX is down 38.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 27.4%.
Annexon has posted a net loss over the last twelve months (EPS of -$1.01), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Annexon
Company profileAnnexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Douglas E. Love Esq., J.D.
- Headquarters
- Brisbane, CA
- Employees
- 97
- IPO year
- 2020
- Website
- annexonbio.com
Financial highlights
Full financialsAnnexon reported a net loss of $206.7 million, compared with a loss of $138.2 million a year earlier. Diluted earnings per share came in at -$1.34.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-206.69M | $-138.20M | $-134.24M | $-141.95M | $-130.32M |
| EPS (diluted) | $-1.34 | $-1.01 | $-1.77 | $-2.60 | $-3.40 |
Analyst forecast
ForecastConsensus (10 analysts)
buy
Avg. price target
$17.00+448.39%
- Strong buy 2
- Buy 6
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-0.25 vs $-0.28
- Surprise
- +10.71%
ANNX news
All ANNX news- Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Annexon, Inc. Reports Third Quarter 2026 Financial Results and Strategic Credit Facility of up to $200 millionNasdaqANNX, BF.A
- Annexon Biosciences GAAP EPS of -$0.25Seeking Alpha
- Annexon Reports Third Quarter 2026 Financial Results, Business Updates and Key Anticipated MilestonesGlobeNewswire
- Commit To Buy Annexon At $2, Earn 100% Annualized Using OptionsNasdaq
- Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
Annexon peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| IMMXImmix Biopharma Inc. | 6.96 | -1.14% | $583.33M | vs ANNX |
| DSGNDesign Therapeutics Inc. | 9.02 | -3.22% | $577.61M | vs ANNX |
| OLMAOlema Oncology Inc. | 7.02 | -1.82% | $615.00M | vs ANNX |
| ABUSArbutus Biopharma Corporation | 4.02 | -1.23% | $616.24M | vs ANNX |
| JANXJanux Therapeutics Inc. | 10.08 | -2.04% | $616.73M | vs ANNX |
| GERNGeron Corporation | 0.8707 | -4.63% | $560.94M | vs ANNX |
| BCAXBicara Therapeutics Inc. | 8.44 | -7.46% | $560.31M | vs ANNX |
| ANLAdlai Nortye Group Ltd. ADR | 8.55 | -5.63% | $550.60M | vs ANNX |
Indexes, lists and sector
Annexon stock FAQ
What is Annexon's stock price today?
ANNX last traded at $3.10 as of Nov 20, 4:00 PM EST, down 9.09% on the day. Prices are delayed at least 15 minutes.
Who is Annexon's CEO?
Mr. Douglas E. Love Esq., J.D. is the chief executive officer of Annexon Inc., which has about 97 employees.
What is the ANNX 52-week high?
The 52-week high for ANNX is $7.18 and the 52-week low is $3.07. The stock is currently 56.8% below its high.